Moexipril hydrochloride

This classification denotes an ace inhibitor with the molecular formula C27H34N2O7.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q1UMG3UH45, chemically known as 3-isoquinolinecarboxylic acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-, monohydrochloride, (3s-(2(r*(r*)),3r*))- but more generally known as moexipril hydrochloride, which bears US NIH Compound Identifier 54889. European Medicines Agency schedules Moexipril hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03312MIG. Most nations, for tariff and trade purposes, schedule moexipril hydrochloride under HS 29334990 and SITC 51575. As of Q4 2014, MOEXIPRIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Moexipril hydrochloride bears US NLM identifiers UMLS ID C0771294 and NCI Concept Code C29267. SMILES: CCOC(=O)[C@H](CCC1CCCCC1)N[C@@H](C)C(=O)N2CC3CC(C(CC3C[C@H]2C(=O)O)OC)OC.CL.